MINERALYS THERAPEUTICS INC. - COMMON STOCK

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

15 May 2023 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

02 May 2023 08:00:02 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023

01 May 2023 08:00:02 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023

27 Apr 2023 16:47:56 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

15 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

04 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

01 Mar 2023 16:05:01 By Nasdaq GlobeNewswire

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

20 Feb 2023 08:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

14 Feb 2023 16:01:00 By Nasdaq GlobeNewswire